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A 27-year-old female presented with a history of a right chest wall tumor at 3 years of age. At that time, the tumor was
surgically resected and diagnosed as Ewing’s sarcoma (EWS), and postoperative chemoradiotherapy was administered.
The patient remained disease-free for 25 years. At age 27, chest computed tomography revealed a mass adjacent to
the anterolateral thoracic wall. After surgery, the diagnosis was primitive neuroectodermal tumor (PNET). She died of
the disease 10 months later. PNET and EWS were integrated into a single item in the 2002 WHO classification; thus, they
are considered clinically and pathologically identical. The morphologic, immunohistochemical, and molecular biological
characteristics of both specimens showed that the second tumor was a local recurrence of Ewing’s sarcoma family of
tumors (ESFT). Our case is the longest duration local recurrence reported. Long-term recurrences of ESFT and patients
with recurrent ESFT have a poor prognosis; thus, long-term follow-up is necessary.
Keywords: Ewing’s sarcoma family of tumors; Primitive neuroectodermal tumor; Late recurrenceBackground
Tumors of Ewing’s sarcoma family of tumors (ESFT) are
malignant tumors that originate in the central and per-
ipheral nervous systems and soft tissues in children and
adolescents. The prognosis is generally poor. However,
recent treatment outcomes of ESFT have improved with
the use of multimodal therapy [1]. Advances in molecu-
lar biology have revealed common chromosomal translo-
cations such as EWS-FLI-1 among Ewing’s sarcoma
(Ewing’s sarcoma of the bone and extraosseous Ewing’s
sarcoma) and related diseases, such as primitive neu-
roectodermal tumor (PNET) and Askin’s tumor [2].
PNET and Ewing’s sarcoma (EWS) were integrated
into a single item in the 2002 WHO classification; thus,
they are considered clinically and pathologically identi-
cal. Late relapses are seldom described. We report a pa-
tient with an ESFT who had a recurrence 25 years after
initial surgery and postoperative chemoradiation.* Correspondence: yun20081113@yahoo.co.jp
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A patient presented to us with a remote history of treat-
ment for a right chest wall tumor. At 3 years of age, she
was noted to have a very large chest wall tumor in the
right thoracic cavity (Figure 1a) without distant metasta-
ses; she subsequently underwent surgical resection. The
specimen revealed malignant small round cells with
rosette formation and was positive for CD99 (MIC2 gene
product) by immunohistochemical staining, consistent
with a diagnosis of EWS (Figure 1b,c,d). The patient was
administered three cycles of postoperative chemotherapy
that consisted of vincristine, cyclophosphamide, adria-
mycin, and actinomycin-D, as well as local irradiation
with a total dose of 40 Gy. Her postoperative course was
uneventful, and she remained disease-free for 25 years.
At 27 years of age, she was referred to our institution
with the chief complaint of chest pain. Her chest X-ray
demonstrated a well-defined, round mass in the right
upper lung field. A computed tomography (CT) scan of
the chest revealed a distinct mass adjacent to the antero-
lateral thoracic wall (Figure 2a), and metastatic workup
was negative. Physical examination was unremarkable.
Hematology and blood chemistry values were within the
normal ranges, and tumor markers (carcinoembryonic anti-
gen, neuron-specific enolase, squamous cell carcinoma-distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Figure 1 Diagnostic results at 3 years of age. (a) Thoracic magnetic resonance imaging at the time of initial surgery. (b) Macroscopic findings of the
resected specimen at the time of initial surgery. (c) Sheets of small round cells with rosette formation (hematoxylin-eosin, ×400). (d) Immunohistochemical
staining for CD99 antibody (×200). The tumor cell membrane stained positively for CD99.
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standard values.
As either radiation-induced sarcoma or a local recur-
rence of EWS was suspected, we performed extirpation
of the tumor and chest wall (the left second to the
fourth ribs), partial resection of the right lung, andFigure 2 Diagnostic results at 27 years of age. (a) Chest computed tomog
seen on the right upper lobe. (b) Resected specimen at the time of recurre
surface is smooth. The cut surface demonstrates a yellow-white, solid comp
findings (hematoxylin-eosin, ×200). The tumor was composed of small roun
vessels. (d) Immunohistochemical staining for CD99 (×200). The tumor cellreconstruction of the chest wall (Figure 2b). Intraopera-
tive blood loss was 800 g, and the operation took 4 h
and 51 min.
Pathologic findings were identical to those of the ori-
ginal chest wall tumor, with small round cells and exten-
sive necrosis (Figure 2c). The specimen stained positivelyraphy findings at the time of recurrence. A well-defined round mass is
nce. The surgical specimen is a 55 × 40 × 40-mm soft tumor. The
onent with hemorrhage and focal necrosis. (c) Histopathological
d tumor cells that showed a rosette-like arrangement around the
membrane stained positively for CD99.
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cal and histochemical staining showed that the tumor was
positive for chromogranin, synaptophysin, and neuron-
specific enolase and negative for thyroid transcription
factor-1, myogenin, and desmin. Fluorescence in situ
hybridization analysis using a EWSR1 break-apart probe
identified the rearranged EWSR1 gene in both cases.
Thus, histopathologically, the tumor was diagnosed as a
PNET. Four cycles of VDC (vincristine, doxorubicin,
cyclophosphamide) chemotherapy and two cycles of IE
(ifosfamide, etoposide) and high-dose L-PAM (melphalan)
and radiotherapy of left thigh bone for a total dose of
30 Gy was administered after the second operation. She
had recurrences in the right chest wall and upper middle
lobe and metastases in the skull, rib, vertebrae, ilium, and
thigh bone. She died of carcinomatous lymphangiosis
10 months after the second surgery.
Discussion
In 1921, James Ewing reported a rare type of sarcoma in
children, adolescents, and young adults that is a highly
malignant tumor of the bone and soft tissue, composed
of small round cells [3]. Separately, Stout et al. reported
in 1918 that a PNET is an ulnar nerve-derived small
round cell tumor with rosette formation that develops in
soft tissues in young individuals [4]. The first small
round cell tumor of chest wall origin was reported in a
pediatric patient by Askin, and these tumors are referred
to as Askin tumors [5]. An Askin tumor is a PNET that
develops from the soft tissues of the chest wall in child-
hood. At that time, our case might have been termed an
Askin tumor.
Pathologically, EWS/PNET is composed of small,
round, uniform cells with characteristic small-sized ros-
ette formation. These tumors, both with a poor progno-
sis, were described as separate entities in the small
round cell tumor group in the second version of the
WHO classification published in 1993. However, with re-
cent improvements in molecular biology, a translocation
(11; 22) (q24; q12) specific to both EWS and PNET has
been identified, and the EWS-FLI-1 fused gene was identi-
fied at the cleavage site of this translocation. They there-
fore were subsequently integrated into a single item
(Ewing’s sarcoma/PNET) in the WHO classification, pub-
lished in 2007 [6]. The ESFT includes EWS of the bone,
extraosseous EWS, and PNET of the bone or soft tissue.
The most useful immunohistologic reagent for the
diagnosis of ESFT is the monoclonal antibody CD99,
which recognizes a cell surface protein. Specimens stain
strongly positive with the CD99 antibody in more than
90% to 95% of cases of reported ESFT.
Chest wall ESFT tumors are rare, have a high rate of
local recurrence, and frequently are metastatic at presen-
tation. In a report of 84 thoracic PNET cases by Biswaset al., patient age ranged from 3 to 40 years (mean age =
15 years) and tumor diameter ranged from 1.6 to
20.0 cm (mean diameter = 9.0 cm). It occurred most
commonly in the ribs (54%), the scapula (25%), and the
chest wall (14%), with a male predominance (70%).
Twenty-seven (32%) patients had metastatic disease at
diagnosis. An independent prognostic factor for PNET is
the presence of metastatic disease [7]. The median
relapse-free interval (RFI) after treatment was 17 months
(range, 5 to 90 months). In contrast to the dramatic im-
provement in survival for ESFT, the prognosis after re-
current disease remains poor, especially for patients with
a RFI of less than 24 months [8].
The morphologic, immunohistochemical, and molecu-
lar biological characteristics from both specimens sup-
ported that the second tumor was a local recurrence of
an ESFT. Several prior studies established that the lon-
gest time until recurrence of ESFT was 19 years [9]. Our
case demonstrates the possibility of very late local recur-
rence of ESFT.
We report a case of locally recurrent ESFT 25 years after
initial treatment. To our knowledge, no case with such late
local relapse as our case has been reported to date.
Conclusions
We report a rare case of chest wall ESFT in a 27-year-
old female. A right thoracic recurrence was surgically
resected 25 years after the primary tumor, but the pa-
tient died of the disease 10 months after surgery. Our
case suggests that patients with ESFT should undergo
lifetime surveillance. Generally, it is difficult to detect re-
currence from clinical symptom of the patients. Patients
should be under observation using periodical CT, bone
scintigraphy, or PET periodically.
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